- Home
- TGB vs LENZ Comparison
TGB vs LENZ Comparison
Compare TGB & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | LENZ |
|---|---|---|
| Founded | 1966 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 551.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TGB | LENZ |
|---|---|---|
| Price | $5.60 | $15.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 6.0M | 1.2M |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $428,559,326.00 | $17,500,000.00 |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $61.39 | $204.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.50 | N/A |
| 52 Week Low | $1.67 | $15.70 |
| 52 Week High | $5.92 | $50.40 |
Technical Indicators
Market Signals| Indicator | TGB | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 26.71 |
| Support Level | $5.52 | $16.49 |
| Resistance Level | $5.92 | $17.67 |
| Average True Range (ATR) | 0.22 | 1.70 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 61.59 | 6.97 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.